Surprise
in Lab Helps ID Drug to Fight ALS.
THURSDAY,
Jan. 24 (HealthDay News) -- A drug that nearly
doubles the life span of mice with inherited amyotrophic lateral sclerosis
(ALS) has been identified by University of Iowa researchers, who made the finding
after discovering an unexpected reaction between proteins in the lab.
The
study results, published online Jan.
The
researchers were studying the basic biology of cell signaling
when they made the unexpected discovery that superoxide
dismutase-1 (SOD1) -- a protein that's mutated in inherited forms of ALS --
interacts with Rac1, a protein that regulates production of reaction oxygen
species (ROS) by the Nox2 protein complex.
ROS
is essential for normal cell function, but abnormal ROS production is a
suspected cause of ALS and other neurodegenerative diseases.
This
unexpected interaction prompted the researchers to take a closer look.
They first found that deletion of the Nox2 protein
almost doubled the life span of mice with inherited ALS. This provided further
evidence that Nox-2 generated ROS may play a role in ALS progression. The
researchers then found that a drug called apocynin,
which blocks Nox2, slows ALS progression and increases life span of mice with
inherited ALS.
About 5 percent to 10 percent of ALS cases in the
There
are no mouse models for sporadic ALS, so the researchers were unable to test
whether apocynin has any effect on sporadic ALS. The
researchers also noted that extensive safety and efficacy testing in
pre-clinical trials must be conducted to determine if apocynin
is effective in people.
The
discovery of the interaction between SOD1 and Rac1 may prove to have widespread
importance.
"It
is exciting not only from the standpoint of ALS, but also because of its
implications for understanding basic cell biology. Rac1 is implicated in many
cellular processes including cellular migration, proliferation and
differentiation, and is an important component of inflammatory disease
processes," team leader John Engelhardt, head of
anatomy and cell biology at UI's Roy J. and Lucille A. Carver College of
Medicine, said in a prepared statement.
--
Robert Preidt
SOURCE:
http://www.medicinenet.com/script/main/art.asp?articlekey=86626